|1.||Lagente, Vincent: 2 articles (03/2005 - 04/2002)|
|2.||Martins, Marco A: 2 articles (03/2005 - 04/2002)|
|3.||Boichot, Elisabeth: 2 articles (03/2005 - 04/2002)|
|4.||Seeger, Werner: 1 article (01/2015)|
|5.||Pichl, Alexandra: 1 article (01/2015)|
|6.||Weissmann, Norbert: 1 article (01/2015)|
|7.||Parajuli, Nirmal: 1 article (01/2015)|
|8.||Grimminger, Friedrich: 1 article (01/2015)|
|9.||Seimetz, Michael: 1 article (01/2015)|
|10.||Bednorz, Mariola: 1 article (01/2015)|
12/01/1994 - "Furthermore, RP 73401 administered directly into the airways, protects against allergic airway inflammation. "
12/01/1994 - "1. We have investigated the effects of RP 73401, a novel, potent and highly selective cyclic nucleotide phosphodiesterase (PDE) type IV inhibitor, in guinea-pig and rat models of bronchoconstriction and allergic inflammation. "
10/26/2006 - "In this study, piclamilast, a selective PDE4 inhibitor, was used to investigate the role of PDE4 in respiratory function and inflammation in a murine asthma model. "
04/01/2001 - "Interestingly, the PDE 4 inhibitor RP 73401 (100 mg kg(-1)) significantly reduced both TNF-alpha levels and neutrophilic inflammation. "
10/26/2006 - "This study suggests that inhibition of PDE4 by piclamilast robustly improves the pulmonary function, airway inflammation and goblet cell hyperplasia in murine allergenic asthma."
|3.||Asthma (Bronchial Asthma)
01/01/2004 - "Piclamilast inhibited FMLP-induced respiratory burst of sputum cells in a concentration-dependent manner (asthma: EC50 approximately 100 nM, max. "
09/22/2000 - "Our data suggest that RP 73-401 may modulate tissue remodelling associated with lung inflammatory processes including asthma."
05/01/1995 - "Thus RP 73401 is a very potent and selective PDE IV inhibitor which suppresses eosinophil function suggesting that it may be a useful agent for the treatment of inflammatory diseases such as asthma. "
12/01/1994 - "RP 73401 may have a role as a bronchodilator and, more importantly, as a prophylactic anti-inflammatory agent in the treatment of asthma."
05/27/1994 - "3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide (15j) showed exceptional potency in all tests and may have therapeutic potential in the treatment of asthma."
|4.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|2.||Adrenocorticotropic Hormone (ACTH)
|4.||Type 4 Cyclic Nucleotide Phosphodiesterases
|5.||Transforming Growth Factor beta (TGF-beta)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Phosphodiesterase 4 Inhibitors